# Spiral Genetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spiral-genetics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.spiralgenetics.com
- Total disclosed funding: $3.2M
- Latest round: Series A (Mar 7, 2013)
- Investors on record: 1

## About

Spiral Genetics, Inc. specializes in genomic data analysis, providing innovative solutions for interpreting complex genetic information to enhance research and clinical applications.Founded in 2009 and headquartered in Seattle, US, Spiral Genetics, Inc. delivers advanced genomic analysis tools. The company was acquired by Omicia, Inc. in January 2017 as part of a strategic move to expand its offerings. Jeremy Bruestle was involved in founding the company, contributing to its development within the genomics sector.Spiral Genetics, Inc. provides a suite of genomic analysis tools designed to facilitate the interpretation of genetic data for research and clinical purposes. Their products enable researchers and healthcare professionals to effectively analyze and visualize genetic information, supporting advancements in personalized medicine and innovative therapeutic solutions. The company seeks to address the needs of its clients, which include academic institutions, healthcare organizations, and biopharmaceutical companies across multiple regions, including North America and Europe.Spiral Genetics, Inc. generates revenue through subscriptions and licenses for its genomic software products. The revenue model includes transaction-based fees for services rendered, supporting various research and clinical applications. Specific pricing strategies are tailored to meet the demands of diverse customers in the genomics space, enhancing user engagement and satisfaction.Following its acquisition in January 2017, Spiral Genetics, Inc. plans to leverage recent funding of USD 0.35 mn obtained through a VENTURE DEBT round to enhance its product offerings and expand into new markets. Upcoming product developments focus on improved genomic analysis tools and integrations with other bioinformatics platforms. Targeted expansion includes tapping into emerging markets in Asia and increasing its presence in Europe by the end of 2023 to better serve a growing customer base in the genomics field.

## Funding rounds

- Series A, Mar 7, 2013, $3.2M — Draper Fisher Jurvetson

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A